Mescaline

Psyence BioMed has partnered with Southern Star Research to expand its Phase IIb clinical trial in Australia, focusing on psilocybin-assisted therapy for adjustment disorder in cancer patients.

Psilocybin-assisted psychotherapy significantly reduced anxiety, depression, and other psychological distress in cancer patients, with benefits lasting up to six months.

The FDA rejected Lykos Therapeutics' application for MDMA-assisted therapy for PTSD, requesting additional data despite promising clinical trial results.

Clinical trials show psilocybin-based therapies are relatively safe and effective for mental health conditions, with Compass Pathways and Cybin advancing to Phase 3 trials.

The Department of Veterans Affairs is funding a study on MDMA-assisted therapy for veterans with PTSD and alcohol use disorder, marking a significant shift in psychedelic research.